Intensifying Competition from Technological Innovation and New Entrants and Obsolescence of Existing Technologies
First written in FY2017. 4 of 6 entries say "Restated". Latest entry: FY2026.
4 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「Meanwhile, various technologies for CAR-T therapy targeting solid tumors are being developed worldwide, making the securing of a competitive advantage a challenge.」
The company has reaffirmed its recognition that global technological development in CAR-T therapy for solid tumors makes securing a competitive advantage a challenge. - FY2025WorsenedAnnual report
「Meanwhile, various technologies for CAR-T therapy targeting solid tumors are being developed worldwide, making the securing of a competitive advantage a challenge.」
The company explicitly stated that global technological development in solid-tumor treatments, including GPC-1 CAR-T therapy, makes securing a competitive advantage a challenge. - FY2021RestatedAnnual report
「The number of new entrants, including major companies, is increasing, and we believe there are also many potential competitors considering entry while advancing their research and development.」
The company has reaffirmed the risk of intensified competition due to technological innovation, new entrants, and competitors’ capabilities, costs and financial resources. - FY2020RestatedAnnual report
「The number of new entrants, including major companies, is increasing, and we believe there are also many potential competitors considering entry while advancing their research and development.」
The company has reaffirmed the risk of intensified competition due to rapid technological innovation, new entrants, and competitors’ capabilities, costs and financial resources, among other factors. - FY2018RestatedAnnual report
「The number of new entrants, including major companies, is increasing, and we believe there are also many potential competitors considering entry while advancing their research and development.」
The company has reaffirmed the risk of intensified competition due to rapid technological innovation, new entrants, and competitors’ productivity, sales capabilities and financial resources. - FY2017First statedAnnual report
「The iPS cell field is subject to intense research competition, rapid technological innovation and active entry by new participants, creating a risk that existing technologies will become obsolete.」
The company first systematically described the risk that rapid technological innovation, new entrants and competitors’ financial resources and sales capabilities could prevent it from generating earnings as planned.